Search

Your search keyword '"Hoppe-Tichy T"' showing total 195 results
Start Over Author "Hoppe-Tichy T"
195 results on '"Hoppe-Tichy T"'

1. Bacterial sepsis: Diagnostics and calculated antibiotic therapy

Author

Richter, D. C., Heininger, A., Brenner, T., Hochreiter, M., Bernhard, M., Briegel, J., Dubler, S., Grabein, B., Hecker, A., Kruger, W. A., Mayer, K., Pletz, M. W., Storzinger, D., Pinder, N., Hoppe-Tichy, T., Weiterer, S., Zimmermann, S., Brinkmann, A., Weigand, M. A., and Lichtenstern, C.

Published
2019
Full Text
View/download PDF

2. The German trial on Aciclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE): a multicenter, randomized, double-blind, placebo-controlled trial

Author

Meyding-Lamadé, U., Jacobi, C., Martinez-Torres, F., Lenhard, T., Kress, B., Kieser, M., Klose, C., Einhäupl, K., Bösel, J., Mackert, M-B, Homberg, V., Koennecke, C., Weißheit, G., Claus, D., Kieseier, B., Bardutzky, J., Neumann-Haefelin, T., Lorenz, M. W., Steinmetz, H., Gerloff, C., Schneider, D., Grau, A., Klein, M., Dziewas, R., Bogdahn, U., Jakob, W., Linker, R., Fuchs, K., Sander, A., Luntz, S., Hoppe-Tichy, T., Hanley, D. F., von Kummer, R., and Craemer, E.

Published
2019
Full Text
View/download PDF

4. Bakterielle Sepsis: Diagnostik und kalkulierte Antibiotikatherapie

Author

Richter, D. C., Heininger, A., Brenner, T., Hochreiter, M., Bernhard, M., Briegel, J., Dubler, S., Grabein, B., Hecker, A., Krüger, W. A., Mayer, K., Pletz, M. W., Störzinger, D., Pinder, N., Hoppe-Tichy, T., Weiterer, S., Zimmermann, S., Brinkmann, A., Weigand, M. A., and Lichtenstern, Christoph

Published
2017
Full Text
View/download PDF

26. Bacterial sepsis

Author

Richter, D. C., primary, Heininger, A., additional, Brenner, T., additional, Hochreiter, M., additional, Bernhard, M., additional, Briegel, J., additional, Dubler, S., additional, Grabein, B., additional, Hecker, A., additional, Kruger, W. A., additional, Mayer, K., additional, Pletz, M. W., additional, Storzinger, D., additional, Pinder, N., additional, Hoppe-Tichy, T., additional, Weiterer, S., additional, Zimmermann, S., additional, Brinkmann, A., additional, Weigand, M. A., additional, and Lichtenstern, C., additional

Published
2018
Full Text
View/download PDF

27. Bakterielle Sepsis

Author

Richter, D. C., primary, Heininger, A., additional, Brenner, T., additional, Hochreiter, M., additional, Bernhard, M., additional, Briegel, J., additional, Dubler, S., additional, Grabein, B., additional, Hecker, A., additional, Krüger, W. A., additional, Mayer, K., additional, Pletz, M. W., additional, Störzinger, D., additional, Pinder, N., additional, Hoppe-Tichy, T., additional, Weiterer, S., additional, Zimmermann, S., additional, Brinkmann, A., additional, Weigand, M. A., additional, and Lichtenstern, Christoph, additional

Published
2017
Full Text
View/download PDF

29. Bakterielle Sepsis : Diagnostik und kalkulierte Antibiotikatherapie.

Author

Richter, D. C., Heininger, A., Brenner, T., Hochreiter, M., Bernhard, M., Briegel, J., Dubler, S., Grabein, B., Hecker, A., Kruger, W. A., Mayer, K., Pletz, M. W., Storzinger, D., Pinder, N., Hoppe-Tichy, T., Weiterer, S., Zimmermann, S., Brinkmann, A., Weigand, M. A., and Lichtenstern, C.

Subjects
SEPTICEMIA treatment, SEPSIS, ANTIBIOTICS, PHARMACOKINETICS, BACTERIAL diseases, ANTI-infective agents
Abstract

The mortality of patients with sepsis and septic shock is still unacceptably high. An effective calculated antibiotic treatment within 1 h of recognition of sepsis is an important target of sepsis treatment. Delays lead to an increase in mortality; therefore, structured treatment concepts form a rational foundation, taking relevant diagnostic and treatment steps into consideration. In addition to the assumed infection and individual risks of each patient, local resistance patterns and specific problem pathogens must be taken into account during the selection of anti-infective treatment. Many pathophysiologic alterations influence the pharmacokinetics (PK) of antibiotics during sepsis. The principle of standard dosing should be abandoned and replaced by an individual treatment approach with stronger weighting of the pharmacokinetics/pharmacodynamics (PK/PD) index of the substance groups. Although this is not yet the clinical standard, prolonged (or continuous) infusion of β‑lactam antibiotics and therapeutic drug monitoring (TDM) can help to achieve defined PK targets. Prolonged infusion is sufficient without TDM, but for continuous infusion, TDM is generally necessary. A further argument for individual PK/PD-oriented antibiotic approaches is the increasing number of infections due to multidrug-resistant (MDR) pathogens in the intensive care unit. For effective treatment, antibiotic stewardship teams (ABS teams) are becoming more established. Interdisciplinary cooperation of the ABS team with infectious disease (ID) specialists, microbiologists, and clinical pharmacists leads not only to rational administration of antibiotics, but also has a positive influence on treatment outcome. The gold standards for pathogen identification are still culture-based detection and microbiologic resistance testing for the various antibiotic groups. Despite the rapid investigation time, novel polymerase chain reaction(PCR)-based procedures for pathogen identification and resistance determination are currently only an adjunct to routine sepsis diagnostics, due to the limited number of studies, high costs, and limited availability. In complicated septic courses with multiple anti-infective therapies or recurrent sepsis, PCR-based procedures can be used in addition to treatment monitoring and diagnostics. Novel antibiotics represent potent alternatives in the treatment of MDR infections. Due to the often defined spectrum of pathogens and the practically (still) absent resistance, they are suitable for targeted treatment of severe MDR infections (therapy escalation). (Contribution available free of charge by "Free Access" [ https://link.springer.com/article/10.1007/s00101-017-0396-z ].). [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

31. Topische Arzneimittelanwendung am Ohr

Author

Bayer F and Hoppe-Tichy T

Subjects
General Medicine
Abstract

Arzneimittel zur Anwendung am Ohr können in den verschiedensten Zubereitungsformen vorliegen. In dieser Gruppe sind Ohrentropfen die am häufigsten verordneten, topisch anzuwendenden Zubereitungen. Die Vorteile von Ohrentropfen liegen in der einfachen Anwendung, geringen Compliance-Problemen und im Infektionsbereich bei der schnellen Erzielung von hohen Wirkstoffkonzentrationen am Wirkort. Die Risiken einer Behandlung mit Ohrentropfen sind gering.

Published
2006

39. a Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals

Author

Rieger, C. T., Cornely, O. A., Hoppe-Tichy, T., Kiehl, M., Knoth, H., Thalheimer, M., Schuler, U., Ullmann, A. J., Ehlken, B., Ostermann, H., Rieger, C. T., Cornely, O. A., Hoppe-Tichy, T., Kiehl, M., Knoth, H., Thalheimer, M., Schuler, U., Ullmann, A. J., Ehlken, B., and Ostermann, H.

Abstract

Invasive fungal disease (IFD) causes increasing morbidity and mortality in haematological cancer patients. Reliable cost data for treating IFD in German hospitals is not available. Objective of the study was to determine the institutional cost of treating the IFD. Data were obtained by retrospective chart review in German hospitals. Patients had either newly diagnosed or relapsed acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS). Direct medical cost was calculated from hospital providers perspective. A total of 108 patients were enrolled at 5 tertiary care hospitals, 36 IFD patients and 72 controls. The vast majority of IFD patients (74%) were diagnosed with invasive aspergillosis. On average, the hospital stay for IFD patients was 12 days longer than in control patients. All patients in the IFD group and 89% of patients in the control group received antifungal drugs. Mean direct costs per patient were 51 pound 517 in the IFD group and 30 pound 454 in the control group. Incremental costs of 21 pound 063 were dominated by cost for antifungal drugs (36%), hospital stay (32%) and blood products (23%). From the perspective of hospitals in Germany the economic burden of IFD in patients with AML or MDS is substantial. Therefore, prevention of IFD is necessary with respect to both clinical and economic reasons.

Published
2012

45. Update: invasive Pilzinfektionen

Author

Lichtenstern, C., primary, Swoboda, S., additional, Hirschburger, M., additional, Domann, E., additional, Hoppe-Tichy, T., additional, Winkler, M., additional, Lass-Flörl, C., additional, and Weigand, M.A., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results